Hyperinsulinism due to activating mutations of glucokinase

Frontiers in Diabetes

Volumn 21, Issue , 2012, Pages 146-157

  Sayed, Samir ^a   Matschinsky, Franz M ^b   Stanley, Charles A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; GLUCOKINASE; GLUCOSE; LEUCINE; OCTREOTIDE; PROTEIN; TRIACYLGLYCEROL;

ARTICLE; BINDING SITE; GENE MUTATION; GENOTYPE; GLUCOKINASE HYPERINSULINISM; GLUCOSE OXIDATION; GLYCOLYSIS; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSULIN RELEASE; MISSENSE MUTATION; MOLECULAR GENETICS; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84859170462     PISSN: 02515342     EISSN: 16622995     Source Type: Book Series    
DOI: 10.1159/000334521     Document Type: Article

References (25)

1. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short-and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637-643.
2. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226-230.
3. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F: The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 2002;51:1240-1246.
4. Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK: Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. J Intern Med 2004;255:143-145.
5. Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, Midgley P, Shiota C, Buettger C, Magnuson MA, Matschinsky FM, Hattersley AT: Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 2003;52:2433-2440.
6. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, Lopez-Enriquez S, Garcia-Gimeno MA, Sanz P, Soriguer FC, Laakso M: Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004;53:2164-2168.
7. Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, Fenneberg A, Debatin KM, Klein R, Ellard S, Clark A, Gloyn AL: Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med 2007;24:1393-1399.
8. Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, Ellard S, Njølstad PR, Alm J, Jacobson BB, Hussain K, Gloyn AL: Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol 2008;159:27-34.
9. Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodriguez-Bada P, Garcia-Gimeno MA, Baixeras E, Weber J, Olek K, Sanz P, Mayatepek E, Cuesta-Munoz AL: Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res 2009; 41:320-326.
10. Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, Suchi M, Taub R, Grimsby J, Matschinsky FM, Stanley CA: Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes 2009;58:1419-1427.
11. Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, Rodriguez-Bada P, Colombo C, Lenzi L, Garcia-Gimeno MA, Bermudez-Silva FJ, de Fonseca FR, Banin P, Aledo JC, Baixeras E, Sanz P, Cuesta-Munoz AL: Opposite clinical phenotypes of glucokinase disease: description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Mol Endocrinol 2009;23:1983-1989.
12. Kassem S, Bhandari S, Rodríguez-Bada P, Motaghedi R, Heyman M, García-Gimeno A, Cobo-Vuilleumier N, Sanz P, Maclaren NK, Rahier J, Glaser B, Cuesta-Muñoz AL: Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med 2010;362: 1348-1350.
13. Beer NL, van de Bunt M, Colclough K, Lukacs C, Arundel P, Chik C, Grimsby J, Ellard S, Gloyn AL: Discovery of a novel site regulating glucokinase activity following characterisation of a new mutation causing hyperinulinaemic hypoglycaemia in humans. J Biol Chem 2011;286:19118-19126.
14. Gloyn AL, Odili S, Buettger C, Njolstad PR, Shiota C, Magnuson MA, Matschinsky FM: Glucokinase and the regulation of blood sugar; in Matschinsky FM, Magnuson MA (eds): Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Basel, Karger, 2004, pp 92-109.
15. Liang Y, Kesavan P, Wang LQ, Niswender K, Tanizawa Y, Permutt MA, Magnuson MA, Matschinsky FM: Variable effects of maturity-onsetdiabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme. Biochem J 1995;309:167-173.
16. Gloyn AL: Glucokinase (GCK) mutations in hyperand hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 2003;22:353-362.
17. Matschinsky FM: Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 2002;51(Suppl. 3):S394-S404.
18. van Schaftingen E, Viega da Cunha M: Discovery and role of glucokinase regulatory protein; in Matschinsky FM, Magnuson MA (eds): Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Basel, Karger, 2004, pp 193-207.
19. Veiga da Cunha M, Courtois S, Michel A, Gosselain E, and Van Schaftingen E: Amino acid conservation in animal glucokinases: identification of residues implicated in the interaction with the regulatory protein. J Biol Chem 1996;271:6292-6297.
20. Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA. Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem 1999;274:37125-3713.
21. Pino MF, Kim KA, Shelton KD, Lindner J, Odili S, Li C, Collins HW, Shiota M, Matschinsky FM, Magnuson MA: Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations. J Biol Chem 2007;282:13906-13916.
22. Pal P, Miller BG: Activating mutations in the human glucokinase gene revealed by genetic selection. Biochemistry 2009;48:814-816.
23. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE: Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-373.
24. Matschinsky FM: Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8:399-416.
25. Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, Naji A, Sarabu R, Grimsby J: Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care 2011;34(Suppl 2): S236-S243.